Sirtuin Mediated Effects of 36 Hour Fast and 1 Hour Exercise
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00978640|
Recruitment Status : Unknown
Verified June 2012 by University of Aarhus.
Recruitment status was: Active, not recruiting
First Posted : September 17, 2009
Last Update Posted : June 20, 2012
Hypothesis: during fasting and exercise will there be an activation of sirtuins (Sirt1).
Primarily the investigators will investigate Sirt1 activity in muscle- and fat-biopsies after fasting for 36 hours and after 1 hour of ergometer-cycling at 50 Vo2max.
In addition to this the investigators will investigate the effect of fasting and exercise on the velocity of carbamide synthesis, aminoacid rate of turnover and glucose rate of turnover.
|Condition or disease||Intervention/treatment||Phase|
|Healthy||Other: fast and exercise Other: exercise||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||8 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||Sirtuin Mediated Effects of 36 h Fast and 1 h Exercise|
|Study Start Date :||September 2009|
|Estimated Primary Completion Date :||June 2012|
|Estimated Study Completion Date :||June 2012|
Experimental: fasting and exercise
36 h fast and 1 h ergometer cycling 50% VO2max
Other: fast and exercise
fasting 36 h and exercise 1 h 50% VO2max
1 h ergometer cycling 50% VO2max
exercise 1 h 50% VO2max
- Sirt1 activity [ Time Frame: 60 min ]
- secondary will we investigate the effect of fasting and exercise on the velocity of carbamide synthesis, aminoacid rate of turnover and glucose rate of turnover. [ Time Frame: 4 h ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00978640
|mikkel Holm Vendelbo|
|Århus, Jylland, Denmark, 8000|